PREVENAR offers the broadest serotype coverage of any pediatric pneumococcal conjugate vaccine to help protect infants and children from the 20 serotypes responsible for the majority of currently circulating pneumococcal disease in the EU and globally
With just few days of treatment, the patient started responding well and finally complete clinical resolution of infection was attained
Survodutide has potential to become best-in-class treatment for metabolic dysfunction-associated steatohepatitis
Net product sales in the fourth quarter of 2023 include the recognition of $0.6 billion from deferred revenue, related to Gavi, the Vaccine Alliance
VELSIPITY is the first and only oral advanced ulcerative colitis therapy approved for use in patients 16 years of age or older in the EU
Pelabresib recently met its primary endpoint of spleen volume reduction and demonstrated favorable trends in symptom improvement
Keynote -564 is the first Phase 3 trial to demonstrate superior overall survival (OS) with adjuvant therapy compared to placebo in patients with RCC
Keytruda is the first and only anti-PD-1 therapy approved in combination with chemoradiotherapy for these patients
Submission based on positive results from global phase 3 study demonstrating overall survival benefit of TIVDAK over chemotherapy
The deal includes upfront payments, milestone payments and ongoing royalties
Subscribe To Our Newsletter & Stay Updated
